Lonicera Innovation research is focused on developing a new approach directed towards prevention of disease, or on reversing early stages of disease. The intestinal microorganisms (the microbiota) have a profound influence on human health,
and an imbalance within the microbiota (dysbiosis) has been shown to lead to development of disease.
The number of individuals with inflammatory-related diseases is increasing, such as colorectal cancer, type-2 diabetes, celiac disease (gluten intolerance) and infertility. Early detection and preventive cost-effective treatment of these diseases will benefit both individuals and society. Our hypothesis is that the microbiota affects expression of mediators in inflammatory pathways in intestinal cells, and that this triggers development of disease. When restoring the normal microbiota by treatment with probiotics, aberrant mechanisms will be reversed and development of disease prevented.